Psoriatic arthritis (PsA) is a chronic inflammatory disease belonging to the family of spondyloarthopathies (SpA). PsA commonly aggravates psoriasis of the skin and frequently manifests as an oligoarthritis with axial skeletal involvement and extraarticular manifestations including dactylitis, enthesitis, and uveitis. The weight of genetic predisposition to psoriasis and PsA is illustrated by the concordance rates in monozygotic twins which clearly demonstrate that genomics is insufficient to induce the clinical phenotype. The association of PsA with several single nucleotide polymorphisms (SNPs) at the IL23R locus and the involvement of Th17 cells in the immunopathogenesis of PsA clearly put the IL-23/IL-17 axis in the spotlight. The IL-23 and IL-17 cytokines have a pivotal role in the chronic inflammation of the synovium in PsA and are also prominent in the skin lesions of those with PsA. In this review, we focus on the genetic association of the IL-23/IL-17 axis with PsA and the contribution of these master cytokines in the pathophysiology of the disease, highlighting the main cell types incriminated in PsA and their specific role in the peripheral blood, lesional skin and joints of patients. We then provide an overview of the approved biologic drugs targeting the IL-23/IL-17 axis and discuss the advantages of genetic stratification to enhance personalized therapies in PsA.

Keywords: genetics, psoriatic arthritis, IL17, IL23, SNPs (single nucleotide polymorphisms), therapy

INTRODUCTION

Psoriatic arthritis (PsA) is a common inflammatory disease affecting the joints and it is usually accompanied by plaque psoriasis (Ps) (1). PsA occurs in up to 30% of patients with psoriasis (particularly those with nail involvement) and affects from 0.05 to 0.25% of the general population (2), making it the second most common form of chronic inflammatory arthritis after rheumatoid disease. To address the therapeutic choices and to envision the potential musculoskeletal and dermatological phenotypes, the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) group identified six disease domains, i.e. peripheral arthritis, enthesitis, dactylitis, axial involvement, skin and nail psoriasis. Among these, peripheral arthritis and enthesitis are dominant and found in the vast majority of patients while the prevalence of axial PsA increases with disease duration, occurring in less than 5% of early referrals and up to 25–70% of patients with long-term disease course for PsA (2). PsA is in some cases characterized by axial...
skeletal involvement, along with the more frequent oligoarthritis with mostly peripheral and asymmetric manifestations (3).

The pathogenetic link between psoriasis and PsA is highly representative of the mechanistic hypotheses of disease pathogenesis. Psoriatic skin is featured by hyperplasia of the epidermis and of the stratum corneum, infiltration of the epidermis by neutrophilic granulocytes (called Munro’s micro abscesses) and infiltration of the dermis by T-cells, dendritic cells (DCs), and macrophages, which leads to the clinical features of raised erythematous silvery plaques (4). In a similar fashion, PsA is characterized by chronic inflammation which causes bone erosion and bone loss, but also new bone formation around the affected joints (5).

The increased number of osteoclasts found in the synovium in PsA is remarkably similar to rheumatoid arthritis (RA) and the persistent inflammatory synovitis causes progressive joint damage due to synovitis and erosion of articular cartilage, visible as radiological damage in almost half of the patients (6). The exaggerated inflammatory response leads to enthesitis, with the crucial contribution of IL-17 producing T-cells and enthesal resident cells, expressing IL-23R (7, 8) with biomechanical stress, HLA-B27, and a permissive microbiome as necessary factors (9).

The phenotypic features of PsA suggest that some of the genetics and molecular mechanisms of the disorder are shared across various different types of inflammatory diseases, including psoriasis, ankylosing spondylitis (AS), inflammatory bowel disease, and Behçet disease (10–12). Extra-articular manifestations of PsA include inflammation of the gastrointestinal tract (with a higher risk of inflammatory bowel disease) and the eye (uveitis), along numerous metabolic and neoplastic disturbances (13).

In this review we will address the contribution of genetics to susceptibility to PsA and its subsequent progression, with special emphasis on the IL-23/IL-17 axis and the genes and cells that this involves. We are well aware that genetics represents only a necessary but insufficient player in the disease etiology, as recapitulated by the low concordance rates in monozygotic twins for PsA. Of note, however, the same rates are for psoriasis among the highest in chronic inflammatory or autoimmune diseases.

**PSA DIAGNOSIS**

The diagnosis of PsA is largely based on features and the CASPAR criteria (14) are used in the research setting for more formal; classification purposes. In contrast to rheumatoid arthritis there are no specific markers or autoantibodies for the diagnosis of PsA: it is seronegative for both rheumatoid factor and antibodies to cyclic citrullinated peptides (CCP) unlike rheumatoid arthritis where these are positive in approximately 80% of cases. Overall PsA is equally distributed between males and females but axial manifestations (spondylitis) are about three times more common in males (15). PsA patients experience substantial functional impairment, decreased quality of life and reduced life expectancy, which highlights the importance of prompt implementation of appropriate treatment. Genetics and molecular studies have led to a better understanding of the etiology of the disease and in future may allow the development of more targeted individual approaches to therapy.

Laboratory tests typically but not invariably show increased raised inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), whereas rheumatoid factor (RF) and CCP antibodies are negative, in contrast to rheumatoid arthritis (16). Recent studies have also shown a possible association with anti-LL37 (cathelicidin antimicrobial peptide) autoantibodies (17).

There is an association with the Human Leukocyte Antigen (HLA)-B27 that is most prevalent in those with sacroiliitis and axial skeletal involvement. Of particular interest, about 85% of PsA patients with bilateral sacroiliitis are positive for HLA-B27 in contrast to only 22% of cases with unilateral sacroiliitis (18, 19). Conversely, HLA-B17/Cw6 haplotype (strongly associated with psoriasis itself) is mostly associated with oligoarthritis (20).

HLA-B27 is the key genetic marker of ankylosing spondylitis (AS), commonly shared with axial-PsA (21). Although the prevalence of HLA-B27 is lower in patients with PsA (20%), it has been demonstrated that axial-PsA patients are significantly HLA-B27 positive compared to patients without axial involvement (P < 0.001) (22, 23).

Radiological imaging of PsA patients may show signs of both bone erosion and new bone formation with bone proliferation mostly found in the metacarpal and metatarsal bones and joints. Formation of new bones is mostly asymmetric, with deformities arising at digits and peripheral joints. Joint damage affects mostly the hands, wrists, feet, ankles, knees, and shoulders. Syndesmophytes may develop in the skeleton and calcification may appear at the entheses, specifically at the insertion sites (24). In contrast to rheumatoid arthritis, PsA may show different manifestations in the same anatomical site with osteolysis and bone deposition detected in the same hand. Dactylitis may be accompanied by bone erosion or new bone formation as well (25). In the spine the degree of new bone formation can be graded using scoring systems, such as the Bath Ankylosing Spondylitis Radiology Index (BASRI) and the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) (26, 27).

**THE GENETICS, EPIGENETICS, AND IMMUNOPATHOGENESIS OF PSA**

There is a strong genetic component to psoriasis and PsA. Further, there is a significant degree of overlap in genetic predisposition between psoriasis, PsA, AS and the inflammatory bowel diseases (ulcerative colitis and Crohn Disease) (21, 28).

The genetic contribution to diseases like psoriasis and PsA has classically been investigated through twin studies. The concordance rate for psoriasis in MZ twins is between 20 to 64%, indicating that genetic factors account for roughly 70% of the population variance in the susceptibility to psoriasis (18). In polygenic diseases, there has also been an increasing focus on monozygotic (MZ) twins in order to assess the influence of epigenetics. This is true also for psoriasis and PsA (29). In addition to genetic predisposition, the onset and progression of
both psoriasis and PsA appear to be influenced by both the environment and epigenetics factors (30).

**Genome-Wide Association Studies and Array-Based Technologies**

PsA is a polygenic immune-mediated disease: genome-wide association studies (GWAS) have identified many genes/genomic loci increasing susceptibility for PsA, many of which are also common to psoriasis uncomplicated by arthritis; these include HLA-A, HLA-B, HLA-C, IL23R, CSF2 (Colonies Stimulating Factor 2 or granulocyte-macrophage colony stimulating factor), TRAF3IP2 (TRAF3 Interacting Protein 2), NOS2 (Nitric Oxide Synthase 2) (31, 32). The results of GWAS suggest that there are PsA-specific genetic variants which are independent of those previously identified in isolated psoriasis, specifically near IL23R and TNFAIP3 (TNFα Induced Protein 3) (33).

GWAS are very informative for common and low frequency variants but they do not identify rare variants. Exome chips, such as the Illumina Exome BeadChip, allow the identification of coding variants and detection of rare SNPs (34). A very good alternative is the ImmunoChip, such as the Illumina Infinium genotyping chip, which contains 196,524 polymorphisms (718 small insertion deletions, 195,806 SNPs) and it is a “low-cost” option. It is designed to perform deep replication of major inflammatory and autoimmune diseases and fine mapping of established GWAS significant loci (35). In 2015, Bowes and colleagues used the ImmunoChip array to fine-map immune-related susceptibility loci including the known psoriasis risk loci, to define new PsA susceptibility loci. They identified a specific PsA variant at the IL23R locus, and a new PsA-specific association at chromosome 5q31 (36).

These associations may indicate roles for certain signaling pathways that are specific to the pathogenesis of PsA rather than psoriasis itself, but further investigation is needed to clearly understand their contribution.

**PsA-Associated Genetic Variants and Their Immune-Pathological Role**

Antigen presentation by MHC proteins is pivotal to acquired immunity, and MHC alleles are strongly associated genetically with both psoriasis and PsA. HLA class I alleles are associated with increased susceptibility for PsA, but the PsA-associated HLA alleles differ from those reported in psoriasis (37). For example, the association of HLA-C*06, which is consistently associated with psoriasis, is only very weakly associated with PsA. Conversely HLA-B*08, HLA-B*27, HLA-B*38, and HLA-B*39 are the HLA alleles most consistently associated with PsA (38).

HLA-B*27, which is the pre- eminent genetic association with AS, is also consistently associated with PsA but not with psoriasis, thereby indicating different pathogenetic mechanisms in the two conditions despite the obvious disease-in-disease bias for case ascertainment. HLA-B*27 is especially associated with axial skeletal disease and the strength of this association tends to show an inverse relationship with the number of peripheral joints involved (39).

Several other genes involved in the immune response are also associated with PsA. Thus, there are also several other non-HLA genetic associations involving components of the MHC class I antigen processing and presentation pathway: these include ERAP1 and ERAP2 (Endoplasmic Reticulum Amino-Peptidase-I and -2). Others are involved in the innate immune response and the initiation of the immune reaction (e.g. TLR4 - Toll-Like Receptor 4), or the differentiation and function of CD8+ T-cells (e.g. RUNX3 - Runt-related transcription factor 3) (31, 40, 41). Many of these genes are also associated with increased susceptibility to AS, highlighting once again the considerable overlap between these two disorders in terms of their genetic susceptibility (42).

The GWAS era has also highlighted several PsA-associated single nucleotide polymorphisms (SNPs) located in IL-23A, IL-23R, IL-12B, TYK2 (Tyrosine Kinase 2), and TRAF3IP2 (which is a downstream target of the IL-17 receptor - IL-17R), implying a pivotal role for the IL-23/IL-17 axis in the pathogenesis of PsA disease pathogenesis (see Table 1) (5, 43). A crucial role for IL-17 family is undisputed as the levels of IL-17 and IL-17R were found increased in both psoriatic skin and synovial fluid of patients with PsA (44).

The contribution of the IL-23/IL-17 axis has greatly advanced our understanding of the pathogenesis of PsA. Th-17 cells produce the pro-inflammatory cytokine IL-17, and all the elements of the Th17 pathway, including MMP3 (Matrix Metalloproteinase 3), CCL1 and CCL20 (Chemokine Ligand 1 and 20) and IL6. The majority of these pro-inflammatory cytokines are upregulated in the blood, synovium, and skin of PsA patients (45, 46). A recent study has identified CXCR6 as a marker for IL-17+CD8+, specialized cells found in the synovial fluid of PsA patients. The presence of CXCR6+IL-17+CD8+ cells in PsA synovium may explain their contribution to the inflammatory environment (47).

| Chromosome | Gene | SNP ID | Odds ratio | Function |
|------------|------|--------|------------|----------|
| 1p31.3 | IL-23R | rs11209026 | 0.6 | Th-17 signaling |
|         |      | rs12044149 | 1.4* |           |
| 2q32.2 | STAT4 | rs7540214 | N/A | Mediating response to IL-12 and Th-17/Th-1 differentiation |
| 5q33.3 | IL12B | rs2082412 | 1.4 | Th-17 and Th-1 differentiation |
|         |      | rs6887695 | 1.35 |           |
|         |      | rs4921482 | 1.43 |           |
|         |      | rs2312227 | 1.44 |           |
|         |      | rs918520 | 1.5 |           |
| 12q13.3 | IL23A | rs2020584 | N/A | Mediating response to IL-12 and Th-17/Th-1 differentiation |
| 17q21.2 | STAT3 | rs744166 | N/A | Th-17 signaling |
|         |      | rs2020584 | N/A |           |
| 5q33.1 | TNIP1 | rs8177833 | 1.8 | NFKB signaling |
| 6q21 | TRAF3IP2 | rs33980500 | 1.7 | Th-17 signaling and NFKB signaling |
|         |      | rs13190932 | N/A |           |
|         |      | rs35251378 | 1.4 | NFKB, Interferon and Th-17 signaling |

1*Odds Ratio (OR) from Stuart PE et al. Am J Hum Genet. 2015 3; 97(6): 816–836.  
2OR from Zhu K et al. Inflamr. Res. 2012; 61, 1149–1154.  
3OR from Bowes et al. Nat Commun. 2015 5; 6: 6046.  
4OR from Filer et al. Arthritis Rheum. 2008; 58(12):3705-9.
IL-23 promotes the survival and expansion of Th-17 cells through its receptor IL23R and the related downstream signaling pathway, which is crucial to Th-17-mediated diseases like PsA. In 2009, a study conducted by Gladman group showed a protective effect for the rs11209026 SNP in IL-23R (encoding the loss-of-function 381Gln allele in the cytoplasmic tail of IL23R) in a Canadian PsA cohort (48). This SNP is also associated with disease severity, while another variant, rs12044149, showed an independent peak of association with PsA, after conditioning for the top SNP associated with psoriasis overall (rs9988642) (36).

Th17-mEDIATE mediatory response also involves the signaling adaptor TRAF3IP2 (TRAF 3-interacting protein 2), which is downstream of IL-17R. The PsA-associated TRAF3IP2 variant rs33980500 alters the binding of the TNF receptor-associated factor 6 (TRAF6), which modulates immunoregulatory signals (49, 50).

IL-23 and IL-17 also have major effects on the activation of osteoclasts, which are the main responsible for bone erosion and where the cytokine RANKL (receptor activator of nuclear factor kappa-B ligand) is a critical factor in the promotion of osteoclasts differentiation. RANKL is also expressed by Th-17 lymphocytes and synovial fibroblasts. The dogma that Th17 cells were the primary responsible for bone resorption was recently challenged in animal studies where cell specific deletion of RANKL indicated that RANKL expression was limited to synovial fibroblasts and B cells (51).

In PsA, bone deposition is crucial as bone resorption. This process arises from the aberrant proliferation, differentiation, and activity of osteoclasts, and several signaling pathways are involved, such as the bone morphogenetic protein (BMP) and the WNT signaling pathway, such as DKK1, and Sclerostin which are relevant for both PsA and AS (52).

The abnormal proliferation of keratinocytes promoting epidermal hyperplasia (53), also emphasizes the predominant functional role of the IL23/IL-17 axis in PsA pathogenesis and in PsA inflammatory cascade.

Lastly, Al Mossawi and colleagues recently demonstrated a marked increase of specific subsets of CD4+ and CD8 + T-cells producing GM-CSF in the blood and synovium of PsA patients. They also demonstrated an increased number of double-positive IL17/GM-CSF for CD4+, CD8+, γδ, and NK (natural killer) cells. The CSF2 locus encoding GM-CSF, is also strongly associated genetically with PsA. Overall these results suggest a functional link between GM-CSF and the IL-17/IL-23 axis, opening important potential avenues for the treatment of PsA, including those targeting GM-CSF directly (54).

**Cell Activation and Innate Immunity**

Inflammation is one of the hallmarks of PsA and activation of the innate immune response is one of the physiological triggers leading to the inflammatory cascade. The transcription factor NF-kB has a major role in this cascade, as it promotes the transcription of several proinflammatory cytokine target genes. Downstream signaling, such as IFNs (Interferons) and TNFα strongly contribute to the immune response in PsA (55).

Several genes involved in these NF-kB pathways show genome-wide significant association with PsA, including REL (a subunit of NF-xB), NOS2, and TNFAIP3 (31, 56). The IL-23/IL-17 axis might also influence the activation of the NF-kB pathway in other ways; these include the adaptor protein Act1, which when is phosphorylated binds to TRAF6 to activate the NF-kB activator protein 1 (AP-1), or the CCAAT-enhancer-binding protein (CEBP) cascade (57).

Interferon signaling also plays a key functional role in the pathogenesis of PsA (58). It is therefore of interest that several interferon-related genes, including TYK2, IFNL1R, and PTPN22, exhibit genome-wide significant association with PsA (59). TYK2, for instance, encodes a tyrosine kinase that is involved in initiating IFNα signaling and, as mentioned above, it is also an activator of IL-23R.

TNFα clearly plays a major role in the inflammatory process of PsA as shown by the presence of raised levels of this cytokine at the sites of inflammation and the dramatic responses to treatment with anti-TNF biologics (60). It has a major role in innate immunity, inducing the production of inflammatory chemokines leading to the accumulation of activated T-cells, neutrophils, and monocytes. It is of some interest that significant association for psoriasis and PsA has been found for the SNPs rs80267959, rs1800629, and rs361525 at the TNFA locus (61).

**Cell Activation and Adaptive Immunity**

The pathogenesis of PsA involves components of both the innate and adaptive immune system. Many different cell types are involved in these pathophysiological processes, including T-cells, neutrophils, keratinocytes, and synoviocytes (62).

The master cytokine in the pathogenesis of PsA is IL23. IL-23 is a heterodimer composed of two subunits p19 and p40 subunits, which bind to IL23R. While p19 is unique to IL-23, the p40 subunit is shared with IL-12 (63). The binding of IL-23 to IL23R leads to the recruitment of JAK2 and TYK2 kinases, which are able to activate IL23R (and its cognate IL12RBI), phosphorylate STAT3 (Signal Transducer and Activator of Transcription 3) and induce RORyT (RAR-related orphan receptor gamma) to promote the differentiation, survival, and expansion of Th-17 cells. IL-23 is essential not only in inducing the Th-17 phenotype but also in defining the level of pathogenicity (64).

Th-17 cells are among the possible drivers of the pathogenesis of PsA and the effector molecules they release are able to trigger different target cells such as osteoclasts, macrophages, and synovial fibroblasts. IL-17 is the major cytokine produced by
Th-17 cells, gd T cells and other various immune cells. IL-17 A is a homodimer disulfide-linked glycoprotein and it is the most widely studied member of the IL-17 cytokines family, which includes also IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F (65). IL-17A and IL-17 F share 55% of homology and they can form heterodimers, which bind the receptor IL-17R. IL-17R is a dimeric complex consisting of two subunits, IL-17RA and IL-17RC subunits (66). The differential binding affinity of IL-17 for IL-17RA and IL-17RC is still not well defined, especially under inflammatory conditions (67).

Th-17 cells differentiate from naïve T-cells depending on a combination of different cytokines along three distinct pathways (68): (i) IL-6 and Transforming Growth Factor-β (TGFβ) (in addition IL-1β and TNFα); (ii) IL-21 and TGFβ; (iii) IL-1β, IL-6, and IL-23 (69). Th-17 cells are characterized by the expression of the transcription factor RORγT with a specific gene signature which in addition to IL17 also includes IL6, TNF, CSF2, CCL20, and IL23R (69).

T-cell subsets triple-positive for IL-17, GM-CSF, TNF, or IFN-γ were found increase in PsA synovial tissue. These enriched polyfunctional cells were also found associated with disease activity index (70).

Recently, an elegant study by Taams’ group demonstrated that IL-17+CD8+T cells may contribute to inflammation and disease persistence in PsA. These cells were found increased in patients’ synovium and have a Th-17 resembling transcriptomic profile characterized by high expression of CXCR6 (47).

JAK and STAT are the key signaling pathways transducing the cytokine signals in Th-17 cells (63). Following the inflammatory cascade mediated by IL-1β and IL-23, Th-17 cells release specific pro-inflammatory cytokines such as IL-17, GM-CSF, and IL-22. The function of Th-17 cells is tightly dependent on the balance of the effector molecules they produced, such as IL-23 and TGF-β, and on those cytokines promoting cell differentiation and maintenance (IL-23).

The effects of IL-23 on bone are conflicting. IL-23, in a Th-17 independent way, up-regulates the expression of the nuclear factor kappa-β ligand RANKL-receptor RANK in osteoclast precursors (from monocyte lineage cells), favoring osteoclast differentiation and proliferation (64, 71). IL-23 also induces the production of GM-CSF, which is an inhibitor of the differentiation of osteoclasts, thus limiting bone resorption (72). RANKL expression is also found in synovial fibroblasts where its deletion plays a key role in bone erosion (51).

Neangiogenesis also appears to have an important part in the pathogenesis of PsA; new blood vessels are prominent in the synovial histology of the condition. It appears that the IL-17/IL-23 axis might play a role in the angiogenic process. As we have described, IL-17 produced by Th-17 cells up-regulates proinflammatory cytokines and prompts the recruitment of neutrophils and macrophages and endothelial cell migration. Further, keratinocytes, stimulated by IL-17 ligands, start to differentiate and proliferate aberrantly, producing proinflammatory adenosine monophosphate (AMP), chemokines, and angiogenic factors such as vascular endothelial growth factor (VEGF) (73).

IL-23 can also promote epidermal hyperplasia activating the proliferation of keratinocytes (increasing the expression of keratin 16) and by acting synergistically with IL-17 promotes the recruitment of neutrophils and the infiltration of IL-22 and IL-17 producing-cells into the lesioned skin (74). The response of keratinocytes and endothelial cells among others to IL-17 and IL-22 stimulation leads to the upregulation of chemokines such as CXCL1 and CCL20, pro-inflammatory cytokines, and antimicrobial peptides, such as LL-37 and β-defensins. IL-17 and IL-22 both promote keratinocyte proliferation and the recruitment of macrophages and neutrophils; they also decrease the expression of adhesion molecules (i.e. selectins and integrins) thus favoring the disruption of the skin barrier. IL-17 can also stimulate the expression of endothelial markers such as P- and E-selectins and adhesion molecules, including ICAM-1 (Intracellular Adhesion Molecule 1) and VCAM-1 (Vascular Cellular Adhesion Molecule 1), which enhances the mobilization of neutrophils (75).

Lastly, the expression of IL-17 and IL-23 is increased in the synovium (76, 77). Gene expression analysis of PsA synovium reveals a gene signature closer to PsA skin than to rheumatoid synovium (78). The recruitment of pathogenic IL-23/IL-17-producing CD4+ T-cells has been demonstrated to be higher in the joints, while the IL-17/IL-22 producing CD4+ T-cells are strongly detected in the skin and in the circulation (79, 80).

**THERAPEUTIC APPROACHES IN PSA**

Since the development of biologic therapies, the ultimate target for the treatment of any patient with psoriasis and/or PsA in modern times is complete remission (81). Initially these targeting TNFα were used with great effect but much effort has also been made to develop biological drugs targeting the IL-23/IL-17 axis. This axis, as specified previously explained, offers several plausible drug targets, such as the p40 subunit of the IL-23/IL-12 receptor, the p19 subunit of IL-23R, IL-17A and its specific receptor IL-17R (82).

In the treatment of PsA non-steroidal anti-inflammatory drugs (NSAID) and synthetic disease modifying antirheumatic drugs [sDMARDs, such as methotrexate (MTX), leflunomide, and sulfasalazine] remain the first-line therapies but biological molecules (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used if therapy with NSAID and DMARDs fails to control the disease adequately.

Biologics (such as etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, and secukinumab) or synthetic drugs (apremilast, tofacitinib and ixekizumab) are given in specific circumstances (62). The different drugs used in PsA (and in other conditions) with their mechanism of action are shown in Table 2.

A combination of two or more of these drugs is often administered in complex immunological diseases like PsA, and often results in increased efficacy compared with monotherapy (83).

In recent few years, a number of guidelines have been developed for the clinical assessment and management of PsA; these include recommendations from GRAPPA, EULAR (European League Against Rheumatology) and ACR/NPF (American College of Rheumatology/National Psoriasis Foundation) (84, 85).
the development program has been continued. However, for PsA or in axial SpA is believed to be marginal and the uncertain as recent data on guselkumab showed efficacy on patient reported outcomes for PsA axial manifestations (91) and a recent phase IV study on ustekinumab reported that this drug is frequently used in patients with axial PsA (92). Inhibition of IL-17A has been achieved using secukinumab, a human monoclonal antibody targeting IL-17A, with efficacy in both PsA and ankylosing spondylitis (93, 94). In the treatment of PsA secukinumab is effective for dactylitis, enthesitis, skin and nail lesions, but its effects on joint disease is rather less, as shown in FUTURE 2 and 3 trials (95).

Targeting the IL-17/IL-23 Pathway

The IL-17/IL-23 pathway and Th-17 cells have become a favorite target in PsA in recent years. For this purpose, several biological drugs have been developed (Figure 1). Ustekinumab, which is a monoclonal antibody targeting p40 subunit of IL-12/IL-23 has been used for skin and nail psoriasis but also for peripheral PsA in those patients who not respond not to DMARDs (87). Two large clinical trials, PHOENIX 1 and 2, assessed the efficacy of ustekinumab in psoriasis patients (88) while PSUMMIT-1 and -2 examined its efficacy and safety in PsA (89). Post-hoc analyses confirmed the efficacy of ustekinumab not only on skin but also in improving PsA rheumatological manifestations and radiographic progression (90). The efficacy of ustekinumab in axial involvement for PsA or in axial SpA is believed to be marginal and the development programs have been thus discontinued. However, the final word on the efficacy of IL23 blockers in SpA remains uncertain as recent data on guselkumab showed efficacy on patient reported outcomes for PsA axial manifestations (91) and a recent phase IV study on ustekinumab reported that this drug is frequently used in patients with axial PsA (92).

For instance, EULAR recommends NSAID and local glucocorticoid injections, especially for enthesitis, in the early phase of the disease. If adverse prognostic factors are present or treatment fails, the administration of sDMARDs, such as MTX (or alternatively leflunomide or sulfasalazine) is recommended (86). If these fail to control the disease adequately or are poorly tolerated the administration of TNF inhibitors should be considered either in combination with DMARDs or not. Biologics should also be used in those with prominent axial disease or severe enthesitis. The continued use of TNF inhibitors should be evaluated carefully according to the patient’s response and a switch to alternative biologics may be considered either where there is no initial benefit (primary failure) or where the response is lost after a period of time (secondary failure) perhaps due to the host generation of antibodies to the biologic (81).

Targeting the IL-17/IL-23 Pathway

The IL-17/IL-23 pathway and Th-17 cells have become a favorite target in PsA in recent years. For this purpose, several biological drugs have been developed (Figure 1). Ustekinumab, which is a monoclonal antibody targeting p40 subunit of IL-12/IL-23 has been used for skin and nail psoriasis but also for peripheral PsA in those patients who not respond not to DMARDs (87).

Two large clinical trials, PHOENIX 1 and 2, assessed the efficacy of ustekinumab in psoriasis patients (88) while PSUMMIT-1 and -2 examined its efficacy and safety in PsA (89). Post-hoc analyses confirmed the efficacy of ustekinumab not only on skin but also in improving PsA rheumatological manifestations and radiographic progression (90). The efficacy of ustekinumab in axial involvement for PsA or in axial SpA is believed to be marginal and the development programs have been thus discontinued. However, the final word on the efficacy of IL23 blockers in SpA remains uncertain as recent data on guselkumab showed efficacy on patient reported outcomes for PsA axial manifestations (91) and a recent phase IV study on ustekinumab reported that this drug is frequently used in patients with axial PsA (92). Inhibition of IL-17A has been achieved using secukinumab, a human monoclonal antibody targeting IL-17A, with efficacy in both PsA and ankylosing spondylitis (93, 94). In the treatment of PsA

DISCUSSION AND CONCLUDING REMARKS: HOW GENETICS MIGHT BE CRUCIAL IN IDENTIFYING CREDIBLE THERAPEUTIC TARGETS

PsA is a complex polygenic disease with a genetic contribution that overlaps with other related conditions such as psoriasis, AS and IBD. Genetic variants associated with a specific disorder have the power to highlight genes or pathways that may contain credible
targets for drug therapy. This is well exemplified for the IL-17/IL-23 axis and Th-17 cells with the development of biological drugs blocking IL-17 (i.e. Secukinumab in AS), or IL-23 (i.e. Ustekinumab in psoriasis/PsA). Unfortunately, the process is challenging (102).

The first crucial point following a GWAS is to accurately assign associated SNPs to the genes they regulate in order to define credible pathways. For this purpose, several experimental functional assays have been developed. Functional disease-associated SNPs may affect the binding of transcription factors or the enrichment of regulatory markers: this is currently evaluated with in vitro Electrophoretic Mobility Shift Assays and ex vivo with Chromatin ImmunoPrecipitation. SNPs may have an effect on gene expression (evaluated with expression quantitative trait loci, eQTL studies) or on chromosome looping (assessed via chromosome conformation assays). Genome editing techniques are performed to define the consequences of harboring a risk variant on cellular function.

Second, these experiments must be performed considering cell-specificity (i.e. specific tissue or cell type) and condition-specificity (i.e. different stimulatory conditions) to provide significant insights into the pathogenesis of a specific disease and develop targeted therapies.

This approach will increase our understanding in defining credible pathways, specific genes, and cell populations for targeted therapy. The better molecular stratification we can achieve (for instance, patients with enrichment of associated SNPs in the IL-23/IL-17 pathway may respond more effectively to secukinumab or ustekinumab), the better the design of personalized therapeutic strategy will be. The final goal will be an advanced use of SNPs as pharmacogenetic markers, in order to define credible pathways to target and predict response to biological therapy (i.e. HLA-C*06 as a pharmacogenetic marker in response to Ustekinumab) (103).

**AUTHOR CONTRIBUTIONS**

MV, VH, BW, and CS conceived the manuscript. MV, VH, CD, MC, BW, and CS drafted the manuscript, and all the authors revised the final version prior to submission. All authors contributed to the article and approved the submitted version.

**FUNDING**

CS is funded by Ministero degli Esteri (Italia), grant ITALY–CHINA - SCIENCE AND TECHNOLOGY COOPERATION: PGR05455. MV is funded by Versus Arthritis#21428, CD is funded by Versus Arthritis#22198.

**ACKNOWLEDGMENTS**

The authors sincerely apologize to those authors whose work is not cited due to space constraints.

**REFERENCES**

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheumat (1973) 3 (1):55–78. doi: 10.1016/0049-0172(73)90035-8
2. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheumat Dis Clinics North Am (2015) 41(4):345–68. doi: 10.1016/j.rdc.2015.07.001
3. Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenic and therapeutic implications. Auto Immun Highlights (2014) 5(1):9–19. doi: 10.1007/s13317-013-0057-4
4. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev (2014) 13(4-5):496–502. doi: 10.1016/j.autrev.2014.01.030
5. O’Rielly DD, Jani M, Rahman P, Elder JT. The Genetics of Psoriasis and Psoriatic Arthritis. J Rheumatol Suppl (2019) 95:46–50. doi: 10.3899/jrheum.190119.

6. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis (2005) 64(Suppl 2):ii4–7. doi: 10.1136/ard.2004.032482.

7. Sherlock JP, Joyce-Shack B, Turner SP, Chao CC, Sather M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammag-+ CD4+CD8- entheseal resident T cells. Nat Med (2012) 18(7):1069–76. doi: 10.1038/nm.2817.

8. Araujo EG, Schett G. Enthesitis in psoriatic arthritis (Part 1): pathophysiology. Rheumatol (Oxford) (2020) 59(Supplement_4):i1–10. doi: 10.1093/rheumatology/kea039.

9. Scher JU, Littman DR, Abramson SB. Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis Rheumatol (2016) 68(1):35–45. doi: 10.1002/art.39259.

10. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med (2010) 10(52):177–83.

11. Ellinghaus D, Jostins L, Spain SL, Cortes A, Pointon JP, Robinson PC, et al. Genome-wide association study identifies three psoriasis susceptibility loci. Nat Genet (2010) 42(11):1000–4. doi: 10.1038/ng.693.

12. Mahoney J, Gustafson D. The Reliability of Laboratory Testing in Psoriatic Arthritis. Clin Exp Rheumatol (2011) 29(5):899–900.

13. Huynh D, Kavaanah A. Psoriatic arthritis: current therapy and future approaches. Rheumatol (Oxford) (2015) 54(1):20–8. doi: 10.1093/rheumatology/keu237.

14. Mahoney J, Gustafson D. The Reliability of Laboratory Testing in Diagnosing Psoriatic Arthritis: A Case Report. J Am Podiatr Med Assoc (2019) 109(6):467–70. doi: 10.7547/17-076.

15. Frasca I, Palazzo R, Chimienti MS, Alverinini S, Tolusso B, Rui L, et al. Anti-L37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. Front Immunol (2018) 9:1936. doi: 10.3389/fimmu.2018.01936.

16. Queiro R, Gonzalez S, Lopez-Larrea C, Alperi M, Sarasqueta C, Riestra JL, et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. J Rheumatol Suppl (2018) 101. doi: 10.1161/jrheum.15.0019.

17. Fond J, Chandran V, Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis (2016) 75(6):1155–62. doi: 10.1136/annrheumdis-2016-209853.

18. Robinson PC, Lau E, Keith P, Lau MC, Thomas GP, Bradbury LA, et al. Development, cytokine profile and function of human interleukin-17 producing helper T cells. Nat Immunol (2007) 8(9):950–7. doi: 10.1038/nilt497.

19. Pollock RA, Abji F, Liang K, Chandran V, Pellet FJ, Virtanen C, et al. Gene expression differences between psoriasis patients with and without
inflammatory arthritis. *J Invest Dermatol* (2015) 135(2):620–3. doi: 10.1038/jid.2014.414

47. Storck KA, Srenathan U, Ridley M, Durham LE, Wu SY, Ryan SE, et al. Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A/CD8+ T Cells in Psoriatic Arthritis. *Arthritis Rheumatol* (2020) 72(3):435–47. doi: 10.1002/art.41158

48. Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. Association of interleukin 23 receptor variants with psoriatic arthritis. *J Rheumatol* (2009) 36(1):137–40. doi: 10.3899/jrheum.080458

49. Hoeffmeier U, Unebe S, Eckie AB, Bowes J, Giardina E, Korendowycz E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. *Nat Genet* (2010) 42(11):996–9. doi: 10.1038/ng.688

50. Bianchi A, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases–new insight from genetics and targeted therapies. *Genes Immun* (2019) 20(5):415–25. doi: 10.1038/s41435-019-0067-y

51. Danks L, Komatsu N, Guerrini MM, Sawa S, Armaka M, Kollias G, et al. Divergence in Skin and Joints. Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Transcriptional Factors and microRNAs. *Front Genet* (2015) 6:236. doi: 10.3389/fgene.2015.00236

52. Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. *Nat Immunol* (2017) 18(6):612–21. doi: 10.1038/nm.4172

53. Wade SM, Canavan M, McGarry T, Low C, Wade SC, Mullan RH, et al. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. *Ann Rheum Dis* (2019) 78(3):350–4. doi: 10.1136/annrheumdis-2018-214318

54. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. *Int Immunopharmacol* (2011) 11(5):543–8. doi: 10.1016/j.intimp.2010.11.010

55. Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. *Nat Rev Rheumatol* (2018) 14(11):631–40. doi: 10.1038/s41584-018-0091-8

56. Cantatore FP, Maruotti N, Corrado A, Ribatti D. Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms. *BioMed Res Int* (2017) 2017:5312813. doi: 10.1155/2017/5312813

57. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic targeting. *Nat Rev Immunol* (2014) 14(9):585–600. doi: 10.1038/nri3707

58. Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Aucuita V, et al. IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. *J Immunol* (2012) 188(12):6287–99. doi: 10.4049/jimmunol.1200385

59. Brentano F, Osplt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and TOLL-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. *Ann Rheum Dis* (2009) 68(1):143–50. doi: 10.1136/ard.2007.082081

60. van Baarsen LG, Lebre MC, van der Coelen D, Aarras S, Tang MW, Ramwadhdoee TH, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? *Arthritis Res Ther* (2014) 16(4):426. doi: 10.1186/s13075-014-0426-z

61. Canete JD, Martinez SE, Forbes J, Sammarit O, Blay M, Gomez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. *Ann Rheum Dis* (2006) 59(4):2653–8. doi: 10.1136/ard.2005.04263

62. Belasco J, Louie JS, Gulati N, Wei N, Nogales K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. *Arthritis Rheumatol* (2015) 67(4):934–44. doi: 10.1002/art.38995

63. Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. *Arthritis Res Ther* (2013) 15(5):R316. doi: 10.1186/ar4317

64. Gossec L, Smolen JS, Ramiro S, de Wit M, Cuttolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* (2016) 75(3):499–510. doi: 10.1136/annrheumdis-2015-208337

65. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. *Curr Opin Rheumatol* (2015) 27(2):127–33. doi: 10.1097/BOR.0000000000000147

66. Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. *Expert Opin Emerg Drugs* (2015) 20(1):1–14. doi: 10.1517/14728721.2015.99378

67. Coates LC, Chandran V, Ogdie A, Sullivan D, Brooke M, Steinkœngi I, et al. International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. *J Rheumatol* (2017) 44(5):684–5. doi: 10.3899/jrheum.170144

68. Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of
Vecellio et al. Genetics of PsA

10

January 2021 | Volume 11 | Article 596086

Copyright © 2021 Vecellio, Hake, Davidson, Carena, Wordsworth and Selmi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

psoriatic arthritis. *Rheumatol* (Oxford) (2017) 56(8):1251–3. doi: 10.1093/rheumatology/kew390

86. Smolen JS, Baeten D, D'Averna J, den Broeder N, Mahler EAM, Hellwell PS, van den Hoogen FJH, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). *Trials* (2020) 21(1):155. doi: 10.1186/s13063-020-0497-6

87. Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. *Ther Adv Musculoskeletal Dis* (2013) 5(5):277–85. doi: 10.1177/1759720X13501021

88. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasn Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. *Br J Dermatol* (2015) 172(5):1371–83. doi: 10.1111/bjd.13469

89. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis* (2014) 73(6):990–9. doi: 10.1136/annrheumdis-2013-204565

90. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase 3 trials, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). *Ann Rheum Dis* (2016) 75(11):1984–8. doi: 10.1136/annrheumdis-2015-209068

91. Mease P, Helliwell P, Gladman D, Poddubnyy D, Baraliakos X, Chakravarty S, et al. OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES, *Ann Rheum Dis* (2020) 79:36–7. doi: 10.1136/annrheumdis-2020-eular.474

92. Smolen JS, Bergmans P, Bondareva I, De Vlam K, Gremese E, Joven-Ibanez B, et al. AR0928 Ustekinumab and tnf inhibitors in psoriatic arthritis: first follow-up data from a routine care study in 8 European countries (PSABIO). *Ann Rheum Dis* (2018) 77:1589–90. doi: 10.1136/annrheumdis-2018-eular.6939

93. Coates LC, Wallman JK, Mcgonagle D, Schett GA, McInnes IB, Mease PJ, et al. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. *Arthritis Res Ther* (2019) 21(1):266. doi: 10.1186/s13075-019-2055-x

94. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in Ankylosing Spondylitis. *N Engl J Med* (2015) 373(26):2534–48. doi: 10.1056/NEJMoa1505066

95. Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). *Arthritis Res Ther* (2018) 20(1):47. doi: 10.1186/s13075-018-1551-x